Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy
2024 · New England Journal of Medicine · 389 citations
https://doi.org/10.1056/nejmoa2305434
S
Simon Gibbs
Epworth Hospital(AU)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
139
Papers
4.9K
Citations
25
h-index
48
i10-index
Simon Gibbs is an academic researcher from Epworth Hospital. The author has contributed to research in topics: Amyloidosis: Diagnosis, Treatment, Outcomes & Multiple Myeloma Research and Treatments & Parathyroid Disorders and Treatments. The author has an h-index of 25, co-authored 119 publications.
ORCID: 0000-0002-1244-4106Papers by this author
worksGuidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group
2022 · Amyloid · 87 citations
https://doi.org/10.1080/13506129.2022.2093635
Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy
2025 · Journal of the American College of Cardiology · 32 citations
https://doi.org/10.1016/j.jacc.2024.11.042
Patterns of late gadolinium enhancement in 94 patients with AL or transthyretin cardiac amyloidosis
2012 · Journal of Cardiovascular Magnetic Resonance · 11 citations
https://doi.org/10.1186/1532-429x-14-s1-o87
P-306 Open-Label Phase 1b Study to Evaluate the Safety and Efficacy of ABBV-383 Monotherapy in Patients With Relapsed or Refractory Light Chain Amyloidosis
2024 · Clinical Lymphoma Myeloma & Leukemia · 0 citations
https://doi.org/10.1016/s2152-2650(24)02208-0
Transthyretin Cardiac Amyloidosis in Australia and New Zealand–A Multi-Site Snapshot for 2022
2024 · Heart Lung and Circulation · 0 citations
https://doi.org/10.1016/j.hlc.2024.05.014
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat